The Cxcr3 antagonist Nbi-74330 attenuates atherosclerotic plaque formation in Ldl receptor deficient mice

被引：0
|
作者：
van Wanrooij, Eva J. [1 ]
De Jager, Saskia C. [1 ]
van Es, Thomas [1 ]
de Vos, Paula [1 ]
Birch, Helen L. [2 ]
Owen, David A. [2 ]
Watson, Robbert J. [2 ]
Biessen, Erik A. [1 ]
Chapman, Gayle A. [2 ]
van Berkel, Theo J. [1 ]
Kuiper, Johan [1 ]
机构：
[1] Leiden Univ, Leiden, Netherlands
[2] UCB, Cambridge, England
来源：
CIRCULATION | 2007年 / 116卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：171 / 172
页数：2
相关论文
共 50 条
  • [1] CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice
    Van Wanrooij, Eva J. A.
    de Jager, Saskia C. A.
    van Es, Thomas
    de Vos, Paula
    Birch, Helen L.
    Owen, David A.
    Watson, Robbert J.
    Biessen, Erik A. L.
    Chapman, Gayle A.
    van Berkel, Theo J. C.
    Kuiper, Johan
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (02) : 251 - 257
  • [2] Dataset of (+/-)-NBI-74330 (CXCR3 antagonist) influence on chemokines under neuropathic pain
    Piotrowska, Anna
    Rojewska, Ewelina
    Pawlik, Katarzyna
    Kreiner, Grzegorz
    Ciechanowska, Agata
    Makuch, Wioletta
    Mika, Joanna
    DATA IN BRIEF, 2018, 21 : 1145 - 1150
  • [3] Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay
    Jopling, L. A.
    Watt, G. F.
    Fisher, S.
    Birch, H.
    Coggon, S.
    Christie, M. I.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (08) : 1260 - 1271
  • [4] CXCR3 antagonist NBI-74330 mitigates joint inflammation in Collagen-Induced arthritis model in DBA/1J mice
    Ahmad, Sheikh F.
    Nadeem, Ahmed
    Ansari, Mushtaq A.
    Bakheet, Saleh A.
    Alomar, Hatun A.
    Al-Mazroua, Haneen A.
    Ibrahim, Khalid E.
    Alshamrani, Ali A.
    Al-Hamamah, Mohammed A.
    Alfardan, Ali S.
    Attia, Sabry M.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 118
  • [5] Identification of Overlapping but Differential Binding Sites for the High-Affinity CXCR3 Antagonists NBI-74330 and VUF11211
    Scholten, Danny J.
    Roumen, Luc
    Wijtmans, Maikel
    Verkade-Vreeker, Marlies C. A.
    Custers, Hans
    Lai, Michael
    de Hooge, Daniela
    Canals, Meritxell
    de Esch, Iwan J. P.
    Smit, Martine J.
    de Graaf, Chris
    Leurs, Rob
    MOLECULAR PHARMACOLOGY, 2014, 85 (01) : 116 - 126
  • [6] Pharmacological blockade of CXCR3 by (±)-NBI-74330 reduces neuropathic pain and enhances opioid effectiveness - Evidence from in vivo and in vitro studies
    Piotrowska, Anna
    Rojewska, Ewelina
    Pawlik, Katarzyna
    Kreiner, Grzegorz
    Ciechanowska, Agata
    Makuch, Wioletta
    Zychowska, Magdalena
    Mika, Joanna
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2018, 1864 (10): : 3418 - 3437
  • [7] Interleukin 9 treatment of LDL receptor deficient mice inhibits atherosclerotic plaque formation
    Kuiper, J
    Von der Thüsen, J
    De Vos, P
    Fekkes, ML
    Van Snick, J
    Biessen, EAI
    Van Berkel, T
    CIRCULATION, 2001, 104 (17) : 320 - 320
  • [8] Aminolevulinic Acid Attenuates Atherosclerotic Plaque Progression of Ldl Receptor Deficient Mice by an Antioxidant Action. An Antioxidant Action
    Hagisawa, Kohsuke
    Morimoto, Yuji
    Nakajima, Motowo
    Ayaori, Makoto
    Ikewaki, Katsunori
    CIRCULATION, 2017, 136
  • [9] Feeding a thermally oxidised fat inhibits atherosclerotic plaque formation in the aortic root of LDL receptor-deficient mice
    Kaemmerer, Ines
    Ringseis, Robert
    Eder, Klaus
    BRITISH JOURNAL OF NUTRITION, 2011, 105 (02) : 190 - 199
  • [10] Bortezomib treatment of LDL receptor deficient mice with advanced atherosclerotic lesions influences plaque composition
    Wilck, N.
    Fechner, M.
    Stangl, K.
    Stangl, V.
    Ludwig, A.
    EUROPEAN HEART JOURNAL, 2012, 33 : 200 - 200
12345